SCHEMBL1078794

SCHEMBL1078794

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1cc2cnc(N)nc2c(-c2ccc(N3CCN(CCO)CC3)nc2)c1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.54
LCK P06239 6/20 0.54
MAPK14 Q16539 5/20 0.54
JAK3 P52333 4/20 0.54
TEK Q02763 3/20 0.54
BRAF P15056 7/20 0.49
RAF1 P04049 6/20 0.49
SRC P12931 1/20 0.48
TYK2 P29597 1/20 0.48
SYK P43405 1/20 0.48
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
MAPK10 P53779 1/20 0.48
BTK Q06187 1/20 0.48
DDR2 Q16832 5/20 0.47
PDGFRB P09619 1/20 0.47
FGFR1 P11362 2/20 0.46
TNK2 Q07912 1/20 0.45
MAP4K2 Q12851 1/20 0.45
KIT P10721 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1079022 0.92 LCK (0.58) KDRLCKMAPK14JAK3TEK
SCHEMBL1078948 0.90 RAF1 (0.63) KDRLCKMAPK14JAK3TEK
SCHEMBL1082787 0.89 LCK (0.56) KDRLCKMAPK14JAK3TEK
SCHEMBL1077635 0.89 LCK (0.56) KDRLCKMAPK14JAK3TEK
SCHEMBL1079339 0.87 LCK (0.55) KDRLCKMAPK14JAK3TEK
SCHEMBL1148554 0.85 LCK (0.56) KDRLCKMAPK14JAK3TEK
SCHEMBL1078638 0.85 KDR (0.57) KDRLCKMAPK14JAK3TEK
SCHEMBL1149545 0.85 RAF1 (0.63) KDRLCKMAPK14JAK3TEK
SCHEMBL1078899 0.84 LCK (0.64) KDRLCKMAPK14JAK3TEK
SCHEMBL1077216 0.84 KDR (0.58) KDRLCKMAPK14JAK3TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 KDR 896/4885LCK 3187/4885MAPK14 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.